ANAPLASTIC LYMPHOMA KINASE
Clinical trials for ANAPLASTIC LYMPHOMA KINASE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LYMPHOMA KINASE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LYMPHOMA KINASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy hopes to control rare lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, alectinib and duvelisib, for people with a rare type of blood cancer called ALK-positive anaplastic large cell lymphoma that has come back or not responded to prior treatment. The goal is to find the safest dose and see if the combinat…
Matched conditions: ANAPLASTIC LYMPHOMA KINASE
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 07:38 UTC
-
Brigatinib under the microscope: how does it really perform in korean patients?
Knowledge-focused Recruiting nowThis study monitors the safety and effectiveness of brigatinib in adults with advanced ALK-positive non-small cell lung cancer in South Korea. Researchers will track side effects and tumor response in 257 patients who start brigatinib for the first time. The goal is to see how we…
Matched conditions: ANAPLASTIC LYMPHOMA KINASE
Sponsor: Takeda • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC